July 03, 2024
Precirix Partners with Orchestra Life Sciences to Expand Access to Radioisotope Lead-212 (Pb-212)
Brussels, Belgium and St. Louis, Missouri, 03 JUL 2024 – Precirix, a leader in the development of precision radiopharmaceuticals using camelid single-domain antibodies as targeting vectors, is proud to announce a strategic partnership with Orchestra Life Sciences, who is developing an innovative Pb-212 generator, the TAG1 generator. This collaboration aims to enhance the availability and application of Pb-212, a promising radioisotope in the field of targeted alpha therapy (TAT) for cancer treatment.
Source: Precirix
